Point72 Asset Management
CTKB icon

Point72 Asset Management’s Cytek Biosciences CTKB Stock Holding History

Point72 Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-114,256
Closed -$577K – 3896
2025
Q4 		$577K Sell
114,256
-73,362
-39% -$341K ﹤0.01% 3169
2025
Q3 		$651K Buy
+187,618
New +$704K ﹤0.01% 1831
2025
Q2 		– Sell
-17,496
Closed -$70.2K – 2262
2025
Q1 		$70.2K Sell
17,496
-371,863
-96% -$1.93M ﹤0.01% 1941
2024
Q4 		$2.53M Buy
+389,359
New +$2.32M 0.01% 1163
2023
Q1 		– Sell
-812,662
Closed -$8.3M – 2289
2022
Q4 		$8.3M Buy
812,662
+139,175
+21% +$1.87M 0.03% 612
2022
Q3 		$9.91M Sell
673,487
-862,592
-56% -$11.2M 0.04% 508
2022
Q2 		$16.5M Buy
1,536,079
+905,079
+143% +$9.01M 0.07% 366
2022
Q1 		$6.8M Buy
+631,000
New +$8.52M 0.03% 615

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's CTKB Position: Q1 2026 in Review

Point72 Asset Management sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 114,256 shares — an estimated $577K sold.

Point72 Asset Management first reported a position in CTKB in Q1 2022 and held it in 8 quarters. The position peaked at $16.5M in Q2 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Point72 Asset Management reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 114,256 Cytek Biosciences shares in Q1 2026, an estimated $577K.
  • Point72 Asset Management first reported a position in Cytek Biosciences in Q1 2022 and held it in 8 quarters.
  • Point72 Asset Management's Cytek Biosciences position peaked at $16.5M in Q2 2022.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.